{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,12]],"date-time":"2026-08-12T17:36:43Z","timestamp":1786556203025,"version":"build-2736575974"},"reference-count":59,"publisher":"Oxford University Press (OUP)","issue":"1","license":[{"start":{"date-parts":[[2026,7,27]],"date-time":"2026-07-27T00:00:00Z","timestamp":1785110400000},"content-version":"vor","delay-in-days":207,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Region Stockholm Center for Innovative Medicine","award":["FoUI-974887"],"award-info":[{"award-number":["FoUI-974887"]}]},{"name":"Vinnova project CAMP","award":["2017-02130"],"award-info":[{"award-number":["2017-02130"]}]},{"name":"the European Community\u2014Next Generation EU","award":["DD3175\/2021"],"award-info":[{"award-number":["DD3175\/2021"]}]},{"name":"the European Community\u2014Next Generation EU","award":["DD3138\/2021"],"award-info":[{"award-number":["DD3138\/2021"]}]},{"name":"National Center for Gene Therapy and Drugs based on RNA Technology","award":["00000041"],"award-info":[{"award-number":["00000041"]}]},{"name":"National Center for Gene Therapy and Drugs based on RNA Technology","award":["E93C22001080001"],"award-info":[{"award-number":["E93C22001080001"]}]},{"name":"Donazione B Cepelli 2025"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,1,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Pediatric brain tumors, particularly pontine diffuse midline glioma (pDMG), remains lethal with limited therapeutic options. Improved stereotactic biopsy techniques and advances in bioinformatics are progressively enabling deeper exploration of immunological vulnerabilities empowering novel strategies, including adoptive cell and gene therapies (ACGTs). We aimed to integrate genomic, transcriptomic, and immunological analyses to identify actionable pathways, surface antigens, and neoantigens that could inform next-generation immunotherapies, including Chimetic Antigen Receptor (CAR)-T cells and T cell Receptor (TCR)-T cell strategies.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Primary pDMG samples (n\u2009=\u20096) underwent whole-genome and RNA sequencing. Transcriptional drug response profiling was used to define targetable transcriptional dependencies. Surface antigen expression and immune cell composition were assessed to evaluate suitability for ACGTs. Neoantigen prediction employed PIOR, integrating somatic variant calling, Human Laukocyte Antigen (HLA) binding, and expression data. Prioritized neoantigens were synthesized and used to stimulate healthy donor T cells. Activated CD137+ T cells were sorted for bulk TCR sequencing to identify clonally expanded TCRs.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Transcriptional drug response profiling revealed heterogeneous but actionable pathway dependencies. B4GALNT1 expression varied across tumors, identifying a subset with GD2 levels compatible with CAR-T targeting. Tumor microenvironment profiling showed enrichment of dendritic cells and M2 macrophages, with scarce CD8+ T cells and NK cells. Across samples, 31 somatic variants were identified including alterations in ACVR1, H3K27M, and TP53. Several predicted neoantigens induced T cell activation and clonal expansion.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>This integrated profiling approach identifies targetable pathways, surface antigens, and neoantigens in pDMG, supporting the development of CAR-T and TCR-T therapies. These insights also suggest potential applicability to other cancers harboring shared mutations.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/noajnl\/vdag193","type":"journal-article","created":{"date-parts":[[2026,7,27]],"date-time":"2026-07-27T11:20:36Z","timestamp":1785151236000},"source":"Crossref","is-referenced-by-count":0,"title":["Immunogenomic profiling reveals targets for gene therapy in pediatric brain tumors"],"prefix":"10.1093","volume":"8","author":[{"given":"Giulia","family":"Rovesti","sequence":"first","affiliation":[{"name":"Department of Oncology and Haematology, Azienda Ospedaliero-Universitaria di Modena , Modena,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alejandro Fernandez","family":"Woodbridge","sequence":"additional","affiliation":[{"name":"NEOGAP Therapeutics AB , Stockholm, (A.F.W., H.G., O.B.N.)","place":["Sweden"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haidong","family":"Yao","sequence":"additional","affiliation":[{"name":"NEOGAP Therapeutics AB , Stockholm, (A.F.W., H.G., O.B.N.)","place":["Sweden"]},{"name":"Department of Laboratory Medicine, Karolinska Institutet , Stockholm,","place":["Sweden"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessia","family":"Pancaldi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chiara","family":"Chiavelli","sequence":"additional","affiliation":[{"name":"Department of Medical and Surgical Sciences of Children and Adults, University of Modena and Reggio Emilia , Modena,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesca","family":"Gatto","sequence":"additional","affiliation":[{"name":"Department of Laboratory Medicine, Karolinska Institutet , Stockholm,","place":["Sweden"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ulrika","family":"Sandvick","sequence":"additional","affiliation":[{"name":"Department of Clinical Neuroscience, BioClinicum, Karolinska Instituet , Solna,","place":["Sweden"]},{"name":"Department of Neurosurgery, Karolinska University Hospital , Solna,","place":["Sweden"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matti","family":"S\u00e4llberg","sequence":"additional","affiliation":[{"name":"Department of Laboratory Medicine, Karolinska Institutet , Stockholm,","place":["Sweden"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4576-9377","authenticated-orcid":false,"given":"Jonas","family":"Fuxe","sequence":"additional","affiliation":[{"name":"Department of Laboratory Medicine, Karolinska Institutet , Stockholm,","place":["Sweden"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Massimo","family":"Dominici","sequence":"additional","affiliation":[{"name":"Department of Oncology and Haematology, Azienda Ospedaliero-Universitaria di Modena , Modena,","place":["Italy"]},{"name":"Department of Medical and Surgical Sciences of Children and Adults, University of Modena and Reggio Emilia , Modena,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hans","family":"Gr\u00f6nlund","sequence":"additional","affiliation":[{"name":"Therapeutic Immune Design, Centre for Molecular Medicine, Department of Clinical Neuroscience, Karolinska Institutet , Stockholm,","place":["Sweden"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ola B","family":"Nilsson","sequence":"additional","affiliation":[{"name":"NEOGAP Therapeutics AB , Stockholm, (A.F.W., H.G., O.B.N.)","place":["Sweden"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniela","family":"Nascimento Silva","sequence":"additional","affiliation":[{"name":"Department of Laboratory Medicine, Karolinska Institutet , Stockholm,","place":["Sweden"]},{"name":"Section for Cell Therapy, Radiumhospitalet, Oslo University Hospital , Oslo,","place":["Norway"]},{"name":"Karolinska ATMP Center, Karolinska Institutet , Stockholm,","place":["Sweden"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5254-2173","authenticated-orcid":false,"given":"Anna","family":"Pasetto","sequence":"additional","affiliation":[{"name":"Department of Laboratory Medicine, Karolinska Institutet , Stockholm,","place":["Sweden"]},{"name":"Pediatric Oncology and Hematology Unit, Department of Medical and Surgical Sciences of Children and Adults, Azienda Ospedaliero-Universitaria di Modena , Modena,","place":["Italy"]},{"name":"Clinical and Experimental Medicine PhD Program, University of Modena and Reggio Emilia , Modena,","place":["Italy"]},{"name":"Section for Cell Therapy, Radiumhospitalet, Oslo University Hospital , Oslo,","place":["Norway"]},{"name":"Department of Oncology, Institute of Clinical Medicine, University of Oslo , Oslo,","place":["Norway"]},{"name":"Karolinska ATMP Center, Karolinska Institutet , Stockholm,","place":["Sweden"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,7,27]]},"reference":[{"key":"2026081212562306900_vdag193-B1","doi-asserted-by":"publisher","first-page":"1231","DOI":"10.1093\/neuonc\/noab106","article-title":"The 2021 WHO classification of tumors of the central nervous system: a summary","volume":"23","author":"Louis","year":"2021","journal-title":"Neuro Oncol"},{"key":"2026081212562306900_vdag193-B2","doi-asserted-by":"publisher","first-page":"110865","DOI":"10.1016\/j.radonc.2025.110865","article-title":"Re-irradiation for children with diffuse intrinsic pontine glioma and diffuse midline glioma","volume":"207","author":"Shariff","year":"2025","journal-title":"Radiother Oncol"},{"key":"2026081212562306900_vdag193-B3","doi-asserted-by":"publisher","first-page":"iii1","DOI":"10.1093\/neuonc\/noac161","article-title":"CBTRUS statistical report: pediatric brain tumor foundation childhood and adolescent primary brain and other central nervous system tumors diagnosed in the United States in 2014\u20132018","volume":"24","author":"Ostrom","year":"2022","journal-title":"Neuro-Oncology"},{"key":"2026081212562306900_vdag193-B4","doi-asserted-by":"publisher","first-page":"861","DOI":"10.1038\/s41591-024-03451-3","article-title":"Intracerebroventricular B7-H3-targeting CAR T cells for diffuse intrinsic pontine glioma: a phase 1 trial","volume":"31","author":"Vitanza","year":"2025","journal-title":"Nat Med"},{"key":"2026081212562306900_vdag193-B5","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1038\/s41698-025-01079-1","article-title":"GD2: hopes and challenges for the treatment of pediatric patients with tumors of the central nervous system","volume":"9","author":"Fern\u00e1ndez-Rilo","year":"2025","journal-title":"NPJ Precis Oncol"},{"key":"2026081212562306900_vdag193-B6","doi-asserted-by":"publisher","first-page":"100210","DOI":"10.1016\/j.ejcped.2024.100210","article-title":"European standard clinical practice recommendations for paediatric high-grade gliomas","volume":"5","author":"Szychot GG","year":"2025","journal-title":"EJC Paediatr Oncol"},{"key":"2026081212562306900_vdag193-B7","doi-asserted-by":"publisher","first-page":"2675","DOI":"10.1007\/s00381-023-06037-5","article-title":"Fifty years of DIPG: looking at the future with hope","volume":"39","author":"Tosi","year":"2023","journal-title":"Childs Nerv Syst"},{"key":"2026081212562306900_vdag193-B8","doi-asserted-by":"publisher","first-page":"100308","DOI":"10.1016\/j.ejcped.2025.100308","article-title":"Temozolomide-based radio-chemotherapy for newly diagnosed pediatric high-grade gliomas (HIT-HGG-2007): a prospective, multicenter, single-arm, phase II trial","volume":"6","author":"Karremann","year":"2025","journal-title":"EJC Paediatr Oncol"},{"key":"2026081212562306900_vdag193-B9","doi-asserted-by":"publisher","first-page":"619","DOI":"10.1080\/02688690802366198","article-title":"Diffuse brainstem gliomas in children: should we or shouldn\u2019t we biopsy?","volume":"22","author":"Leach","year":"2008","journal-title":"Br J Neurosurg"},{"key":"2026081212562306900_vdag193-B10","doi-asserted-by":"publisher","first-page":"342","DOI":"10.1186\/s12967-023-04178-4","article-title":"The Swedish childhood tumor biobank: systematic collection and molecular characterization of all pediatric CNS and other solid tumors in Sweden","volume":"21","author":"D\u00edaz de St\u00e5hl","year":"2023","journal-title":"J Transl Med"},{"key":"2026081212562306900_vdag193-B11","doi-asserted-by":"publisher","first-page":"1773","DOI":"10.1007\/s00381-015-2832-1","article-title":"Biopsy in a series of 130 pediatric diffuse intrinsic pontine gliomas","volume":"31","author":"Puget","year":"2015","journal-title":"Childs Nerv Syst"},{"key":"2026081212562306900_vdag193-B12","doi-asserted-by":"publisher","first-page":"261","DOI":"10.3171\/2017.2.PEDS1665","article-title":"Update on the diagnostic value and safety of stereotactic biopsy for pediatric brainstem tumors: a systematic review and meta-analysis of 735 cases","volume":"20","author":"Hamisch","year":"2017","journal-title":"J Neurosurg Pediatr"},{"key":"2026081212562306900_vdag193-B13","doi-asserted-by":"publisher","first-page":"iii293","DOI":"10.1093\/neuonc\/noaa222.083","article-title":"Dipg-35. BIOLOGICAL medicine for diffuse intrinsic pontine glioma (DIPG) eradication: results of the three arm biomarker-driven randomized BIOMEDE 1.0 trial","volume":"22","author":"Grill","year":"2020","journal-title":"Neuro-Oncology"},{"key":"2026081212562306900_vdag193-B14","doi-asserted-by":"publisher","first-page":"S110","DOI":"10.1093\/neuonc\/noad220","article-title":"H3 K27M-altered glioma and diffuse intrinsic pontine glioma: semi-systematic review of treatment landscape and future directions","volume":"26","author":"van den Bent","year":"2024","journal-title":"Neuro Oncol"},{"key":"2026081212562306900_vdag193-B15","doi-asserted-by":"publisher","first-page":"1023","DOI":"10.1038\/s41467-019-08823-9","article-title":"ACVR1 R206H cooperates with H3.1K27M in promoting diffuse intrinsic pontine glioma pathogenesis","volume":"10","author":"Hoeman","year":"2019","journal-title":"Nat Commun"},{"key":"2026081212562306900_vdag193-B16","doi-asserted-by":"publisher","first-page":"2789","DOI":"10.1093\/neuonc\/noaf163","article-title":"Beyond base camp: PI3K\/mTOR inhibition for the treatment of pediatric high-grade gliomas","volume":"27","author":"Duchatel","year":"2025","journal-title":"Neuro Oncol"},{"key":"2026081212562306900_vdag193-B17","doi-asserted-by":"publisher","first-page":"191","DOI":"10.3389\/fonc.2018.00191","article-title":"CDK4\/6 and PDGFRA signaling as therapeutic targets in diffuse intrinsic pontine glioma","volume":"8","author":"Hoeman","year":"2018","journal-title":"Front Oncol"},{"key":"2026081212562306900_vdag193-B18","doi-asserted-by":"publisher","DOI":"10.1097\/01.COT.0000000000000171"},{"key":"2026081212562306900_vdag193-B19","doi-asserted-by":"publisher","first-page":"1542","DOI":"10.1200\/JCO.23.01134","article-title":"ONC201 (dordaviprone) in recurrent H3 K27M-mutant diffuse midline glioma","volume":"42","author":"Arrillaga-Romany","year":"2024","journal-title":"J Clin Oncol"},{"key":"2026081212562306900_vdag193-B20","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1177\/03008916221099067","article-title":"A homogeneous treatment for non-DIPG diffuse midline glioma","volume":"109","author":"Schiavello","year":"2023","journal-title":"Tumori"},{"key":"2026081212562306900_vdag193-B21","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1007\/s11060-014-1428-z","article-title":"Results of nimotuzumab and vinorelbine, radiation and re-irradiation for diffuse pontine glioma in childhood","volume":"118","author":"Massimino","year":"2014","journal-title":"J Neurooncol"},{"key":"2026081212562306900_vdag193-B22","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1007\/s11060-019-03140-z","article-title":"Nimotuzumab and radiotherapy for treatment of newly diagnosed diffuse intrinsic pontine glioma (DIPG): a phase III clinical study","volume":"143","author":"Fleischhack","year":"2019","journal-title":"J Neurooncol"},{"key":"2026081212562306900_vdag193-B23","doi-asserted-by":"publisher","first-page":"1349612","DOI":"10.3389\/fgene.2024.1349612","article-title":"Current immunotherapeutic approaches to diffuse intrinsic pontine glioma","volume":"15","author":"Lin","year":"2024","journal-title":"Front Genet"},{"key":"2026081212562306900_vdag193-B24","doi-asserted-by":"publisher","first-page":"6689","DOI":"10.1038\/s41467-021-26936-y","article-title":"Proteogenomic discovery of neoantigens facilitates personalized multi-antigen targeted T cell immunotherapy for brain tumors","volume":"12","author":"Rivero-Hinojosa","year":"2021","journal-title":"Nat Commun"},{"key":"2026081212562306900_vdag193-B25","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1186\/s40478-023-01569-y","article-title":"Advanced immunotherapies for glioblastoma: tumor neoantigen vaccines in combination with immunomodulators","volume":"11","author":"Segura-Collar","year":"2023","journal-title":"Acta Neuropathol Commun"},{"key":"2026081212562306900_vdag193-B26","doi-asserted-by":"publisher","first-page":"934","DOI":"10.1038\/s41586-022-04489-4","article-title":"GD2-CAR T cell therapy for H3K27M-mutated diffuse midline gliomas","volume":"603","author":"Majzner","year":"2022","journal-title":"Nature"},{"key":"2026081212562306900_vdag193-B27","doi-asserted-by":"publisher","first-page":"708","DOI":"10.1038\/s41586-024-08171-9","article-title":"Intravenous and intracranial GD2-CAR T cells for H3K27M(+) diffuse midline gliomas","volume":"637","author":"Monje","year":"2025","journal-title":"Nature"},{"key":"2026081212562306900_vdag193-B28","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1158\/2159-8290.CD-22-0750","article-title":"Intraventricular B7-H3 CAR T cells for diffuse intrinsic pontine glioma: preliminary first-in-human bioactivity and safety","volume":"13","author":"Vitanza","year":"2023","journal-title":"Cancer Discov"},{"key":"2026081212562306900_vdag193-B29","doi-asserted-by":"publisher","first-page":"2769","DOI":"10.1200\/JCO.23.02019","article-title":"Phase I trial of GD2.CART cells augmented with constitutive interleukin-7 receptor for treatment of high-grade pediatric CNS tumors","volume":"42","author":"Lin","year":"2024","journal-title":"J Clin Oncol"},{"key":"2026081212562306900_vdag193-B30","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1158\/1078-0432.CCR-13-0945","article-title":"CD137 accurately identifies and enriches for naturally occurring tumor-reactive T cells in tumor","volume":"20","author":"Ye","year":"2014","journal-title":"Clin Cancer Res"},{"key":"2026081212562306900_vdag193-B31","doi-asserted-by":"publisher","first-page":"2491","DOI":"10.1158\/1078-0432.CCR-16-2680","article-title":"Isolation of T-cell receptors specifically reactive with mutated tumor-associated antigens from tumor-infiltrating lymphocytes based on CD137 expression","volume":"23","author":"Parkhurst","year":"2017","journal-title":"Clin Cancer Res"},{"key":"2026081212562306900_vdag193-B32","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1038\/nm.4051","article-title":"Prospective identification of neoantigen-specific lymphocytes in the peripheral blood of melanoma patients","volume":"22","author":"Gros","year":"2016","journal-title":"Nat Med"},{"key":"2026081212562306900_vdag193-B33","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.122467","article-title":"Enhanced detection of neoantigen-reactive T cells targeting unique and shared oncogenes for personalized cancer immunotherapy","author":"Yossef","journal-title":"JCI Insight"},{"key":"2026081212562306900_vdag193-B34","doi-asserted-by":"publisher","first-page":"734","DOI":"10.1158\/2326-6066.CIR-16-0001","article-title":"Tumor- and neoantigen-reactive T-cell receptors can be identified based on their frequency in fresh tumor","volume":"4","author":"Pasetto","year":"2016","journal-title":"Cancer Immunol Res"},{"key":"2026081212562306900_vdag193-B35","doi-asserted-by":"publisher","first-page":"2586","DOI":"10.1038\/s41591-024-03109-0","article-title":"Adoptive transfer of personalized neoantigen-reactive TCR-transduced T cells in metastatic colorectal cancer: phase 2 trial interim results","volume":"30","author":"Parkhurst","year":"2024","journal-title":"Nat Med"},{"key":"2026081212562306900_vdag193-B36","doi-asserted-by":"publisher","first-page":"866763","DOI":"10.3389\/fonc.2022.866763","article-title":"Generation of tumor-specific cytotoxic T cells from blood via In vitro expansion using autologous dendritic cells pulsed with neoantigen-coupled microbeads","volume":"12","author":"Kiessling","year":"2022","journal-title":"Front Oncol"},{"key":"2026081212562306900_vdag193-B37","doi-asserted-by":"publisher","first-page":"1125","DOI":"10.1136\/gutjnl-2024-334148","article-title":"Unlocking novel T cell-based immunotherapy for hepatocellular carcinoma through neoantigen-driven T cell receptor isolation","volume":"74","author":"Maravelia","year":"2025","journal-title":"Gut"},{"key":"2026081212562306900_vdag193-B38","doi-asserted-by":"publisher","first-page":"100340","DOI":"10.1016\/j.xgen.2023.100340","article-title":"OpenPBTA: the open pediatric brain tumor atlas","volume":"3","author":"Shapiro","year":"2023","journal-title":"Cell Genom"},{"key":"2026081212562306900_vdag193-B39","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1038\/s43018-019-0018-6","article-title":"Discovering the anti-cancer potential of non-oncology drugs by systematic viability profiling","volume":"1","author":"Corsello","year":"2020","journal-title":"Nat Cancer"},{"key":"2026081212562306900_vdag193-B40","doi-asserted-by":"publisher","first-page":"1184","DOI":"10.1038\/nprot.2009.97","article-title":"Mapping identifiers for the integration of genomic datasets with the R\/bioconductor package biomaRt","volume":"4","author":"Durinck","year":"2009","journal-title":"Nat Protoc"},{"key":"2026081212562306900_vdag193-B41","doi-asserted-by":"publisher","DOI":"10.1093\/bib\/bbab260","article-title":"oncoPredict: an R package for predicting in vivo or cancer patient drug response and biomarkers from cell line screening data","author":"Maeser","journal-title":"Brief Bioinform"},{"key":"2026081212562306900_vdag193-B42","doi-asserted-by":"publisher","first-page":"e107468","DOI":"10.1371\/journal.pone.0107468","article-title":"pRRophetic: an R package for prediction of clinical chemotherapeutic response from tumor gene expression levels","volume":"9","author":"Geeleher","year":"2014","journal-title":"PLoS One"},{"key":"2026081212562306900_vdag193-B43","doi-asserted-by":"publisher","first-page":"641","DOI":"10.1126\/science.1251102","article-title":"Cancer immunotherapy based on mutation-specific CD4+ T cells in a patient with epithelial cancer","volume":"344","author":"Tran","year":"2014","journal-title":"Science"},{"key":"2026081212562306900_vdag193-B44","doi-asserted-by":"publisher","first-page":"2847","DOI":"10.1093\/bioinformatics\/btw313","article-title":"Complex heatmaps reveal patterns and correlations in multidimensional genomic data","volume":"32","author":"Gu","year":"2016","journal-title":"Bioinformatics"},{"key":"2026081212562306900_vdag193-B45","doi-asserted-by":"publisher","first-page":"D955","DOI":"10.1093\/nar\/gks1111","article-title":"Genomics of drug sensitivity in cancer (GDSC): a resource for therapeutic biomarker discovery in cancer cells","volume":"41","author":"Yang","year":"2013","journal-title":"Nucleic Acids Res"},{"key":"2026081212562306900_vdag193-B46","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1215\/15228517-2008-072","article-title":"Sagopilone crosses the blood-brain barrier in vivo to inhibit brain tumor growth and metastases","volume":"11","author":"Hoffmann","year":"2009","journal-title":"Neuro Oncol"},{"key":"2026081212562306900_vdag193-B47","doi-asserted-by":"publisher","first-page":"2262","DOI":"10.1093\/neuonc\/noad141","article-title":"Phase I trial of panobinostat in children with diffuse intrinsic pontine glioma: a report from the pediatric brain tumor consortium (PBTC-047)","volume":"25","author":"Monje","year":"2023","journal-title":"Neuro Oncol"},{"key":"2026081212562306900_vdag193-B48","doi-asserted-by":"publisher","first-page":"555","DOI":"10.1038\/nm.3855","article-title":"Functionally defined therapeutic targets in diffuse intrinsic pontine glioma","volume":"21","author":"Grasso","year":"2015","journal-title":"Nat Med"},{"key":"2026081212562306900_vdag193-B49","doi-asserted-by":"publisher","first-page":"853","DOI":"10.1038\/ncb2089","article-title":"Heterochromatin formation in the mouse embryo requires critical residues of the histone variant H3.3","volume":"12","author":"Santenard","year":"2010","journal-title":"Nat Cell Biol"},{"key":"2026081212562306900_vdag193-B50","doi-asserted-by":"publisher","first-page":"6950","DOI":"10.1158\/1078-0432.CCR-05-0740","article-title":"In vivo evaluation of ixabepilone (BMS247550), a novel epothilone B derivative, against pediatric cancer models","volume":"11","author":"Peterson","year":"2005","journal-title":"Clin Cancer Res"},{"key":"2026081212562306900_vdag193-B51","doi-asserted-by":"publisher","first-page":"934","DOI":"10.1038\/s41586-022-04489-4","article-title":"GD2-CAR T cell therapy for H3K27M-mutated diffuse midline gliomas","volume":"603","author":"Majzner","year":"2022","journal-title":"Nature"},{"key":"2026081212562306900_vdag193-B52","doi-asserted-by":"publisher","first-page":"E6","DOI":"10.1038\/s41586-024-08452-3","article-title":"Author correction: intravenous and intracranial GD2-CAR T cells for H3K27M(+) diffuse midline gliomas","volume":"636","author":"Monje","year":"2024","journal-title":"Nature"},{"key":"2026081212562306900_vdag193-B53","doi-asserted-by":"publisher","first-page":"976","DOI":"10.1038\/s43018-022-00405-x","article-title":"Transition to a mesenchymal state in neuroblastoma confers resistance to anti-GD2 antibody via reduced expression of ST8SIA1","volume":"3","author":"Mabe","year":"2022","journal-title":"Nat Cancer"},{"key":"2026081212562306900_vdag193-B54","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1038\/s41698-024-00506-z","article-title":"Autologous anti-GD2 CAR T cells efficiently target primary human glioblastoma","volume":"8","author":"Chiavelli","year":"2024","journal-title":"NPJ Precis Oncol"},{"key":"2026081212562306900_vdag193-B55","doi-asserted-by":"publisher","DOI":"10.3390\/cancers17060931","article-title":"Updates in diagnostic techniques and experimental therapies for diffuse intrinsic pontine glioma","author":"McVeigh","journal-title":"Cancers (Basel)"},{"key":"2026081212562306900_vdag193-B56","doi-asserted-by":"publisher","DOI":"10.3390\/cancers17030420","article-title":"Latest advancements in the management of H3K27M-Mutant diffuse intrinsic pontine glioma: a narrative review","volume":"17","author":"Lo Greco","year":"2025","journal-title":"Cancers (Basel)"},{"key":"2026081212562306900_vdag193-B57","doi-asserted-by":"publisher","first-page":"10003","DOI":"10.1200\/JCO.2023.41.16_suppl.10003","article-title":"Biological medicines for diffuse intrinsic pontine glioma (DIPG) eradication (BIOMEDE): final results of an international randomized phase II platform trial comparing 3 targeted therapies in combination with radiotherapy from ITCC, SIOPE-Brain and ANZCHOG","volume":"41","author":"Grill","year":"2023","journal-title":"JCO"},{"key":"2026081212562306900_vdag193-B58","doi-asserted-by":"publisher","first-page":"951","DOI":"10.1200\/JCO.2017.76.0611","article-title":"Phase II, open-label, randomized, multicenter trial (HERBY) of bevacizumab in pediatric patients with newly diagnosed high-grade glioma","volume":"36","author":"Grill","year":"2018","journal-title":"J Clin Oncol"},{"key":"2026081212562306900_vdag193-B59","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2022-005535","article-title":"H3.3K27M mutation is not a suitable target for immunotherapy in HLA-A2(+) patients with diffuse midline glioma","author":"Immisch","journal-title":"J Immunother Cancer"}],"container-title":["Neuro-Oncology Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/noa\/advance-article-pdf\/doi\/10.1093\/noajnl\/vdag193\/70184904\/vdag193.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/noa\/article-pdf\/8\/1\/vdag193\/70184904\/vdag193.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/noa\/article-pdf\/8\/1\/vdag193\/70184904\/vdag193.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,12]],"date-time":"2026-08-12T16:56:31Z","timestamp":1786553791000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/noa\/article\/doi\/10.1093\/noajnl\/vdag193\/8743619"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1]]},"references-count":59,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,1,12]]}},"URL":"https:\/\/doi.org\/10.1093\/noajnl\/vdag193","relation":{},"ISSN":["2632-2498"],"issn-type":[{"value":"2632-2498","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,1]]},"published":{"date-parts":[[2026,1]]},"article-number":"vdag193"}}